Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients.
Data from 20 highly drug-experienced HIV-infected patients receiving tenofovir plus didanosine as part of a salvage regimen were analysed. At baseline, all but one patient harboured a virus bearing at least one nucleoside excision mutation (NEM); in 13 cases (65%) three or more NEM were detectable. After a median of 26 weeks of treatment, two patients (10%) selected the 65R mutation. These results support the hypothesis that NEM hinder the selection of this mutation.
Gianotti
Nicola
N
Clinic of Infectious Diseases, Vita-Salute San Raffaele University, Milan, Italy.
Seminari
Elena
E
Fusetti
Giuliana
G
Salpietro
Stefania
S
Boeri
Enzo
E
Galli
Andrea
A
Lazzarin
Adriano
A
Clementi
Massimo
M
Castagna
Antonella
A
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D004279:DNA, Viral / Q000032:analysis; D030541:Databases, Genetic; D016049:Didanosine / Q000627:therapeutic use*; D024921:Drug Resistance, Multiple, Viral; D017353:Gene Deletion; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D009154:Mutation; D063065:Organophosphonates / Q000627:therapeutic use*; D000068698:Tenofovir
D019380:Anti-HIV Agents; D004279:DNA, Viral; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine; D016049:Didanosine